Form 4: Ligand Pharmaceuticals CLO Andrew Reardon Executes Stock Option and Sells Shares
SEC Form 4
Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, exercised stock options and sold 2,000 shares of common stock on September 23, 2024.
Summary
- On September 23, 2024, Andrew Reardon, the CLO & Secretary of Ligand Pharmaceuticals, exercised stock options to acquire 2,000 shares of common stock at a price of $52.27 per share.
- Simultaneously, Reardon sold 2,000 shares of Ligand Pharmaceuticals common stock at a price of $99.6005 per share.
- Following these transactions, Reardon directly owns 22,534 shares of Ligand Pharmaceuticals common stock.
- Reardon also holds options to purchase 70,944 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing insider trading activity. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it reflects an insider's decision to exercise options and sell shares, which could be interpreted in various ways.
Key Dates
| Date | Description |
|---|---|
| 02/01/2023 | Stock option vests and is exercisable as to 12.5% of the underlying shares. |
| 09/23/2024 | Date of transaction: Exercise of stock options and sale of shares. |
| 09/25/2024 | Date of signature on the Form 4 filing. |
| 08/01/2032 | Expiration date of the employee stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.